Archive
PAREXEL Reports Second Quarter Fiscal Year 2012 Financial Results
- Consolidated service revenue of $333.2 million grew 9.5% year-over-year - GAAP operating margin of 6.8%; adjusted operating margin of 7.1% excluding net restructuring charges of $1.2 mi... [Read more]
Spherix Announces Successful Completion of Important Toxicology Study of SPX-106
Readies IND Filing BETHESDA, MD, Jan 11, 2012 (CRWENEWSWIRE) -- Spherix Incorporated (NASDAQ:SPEX) – an innovator in biotechnology for therapy in diabetes, metabolic syndrome and athero... [Read more]
Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight
Results to Be Presented Wednesday, October 26, at AAPS National Meeting in Washington, DC BETHESDA, MD, Oct. 24, 2011 (CRWENEWSWIRE) -- Spherix Incorporated (NASDAQ:SPEX) -- an innovator in... [Read more]
ProtoKinetix Outlines AAGP™ Values in CEO Interview
VANCOUVER, British Columbia--(CRWENEWSWIRE)-- ProtoKinetix (OTCBB:PKTX.OB) (www.protokinetix.com), a biotechnology company that has developed and patented a family of synthetic anti-aging g... [Read more]
LXP, PWRM, AET, NHPR, TWC - NYSE Stock Reports And Highlights! From PennyToBuck.com
Lexington Realty Trust (NYSE:LXP) announced that it declared a regular common share dividend for the quarter ending June 30, 2011 of $0.115 per common share payable on or about July ... [Read more]
